• Article

Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-To-Severe Rheumatoid Arthritis

Citation

Hicks, K., Earnshaw, S., Shaw, J. W., & Cifaldi, M. (2012). Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-To-Severe Rheumatoid Arthritis. Value in Health, 15(7), A439-A440.